don't worry ..will be 50c soon haha
Printable View
don't worry ..will be 50c soon haha
Certainly no bait intended BC. My point was simply that nobody knows what that next candle is going to do. But to be fair, you have been one of the better "guessers" and as a self confessed "on going" learner of TA, I do take notice of your posts.
Your prediction is logical based on the last few days trading, but as an investor I am also interested in the medium to longer term outlook for PEB and when this current down trend may be broken. FA tells me it will be as soon as CMS, Kaiser etc are confirmed followed by a significant uplift in sales whereas with TA, historically at least - your prediction (based on similar candle behaviour) has happened 3 times previously but the down trend has continued. So, picking the reversal of any trend is an absolute lucky guess...no matter what method is used. Although everyone trades differently, we are all rowing the same boat.
Now, let's see what today brings ....
And then there was this from our old buddy in Otago, - sounds positive at least
Pacific Edge focusing on expansion
Home » News » Business
By Simon Hartley on Thu, 29 May 2014News: Business
http://w.sharethis.com/images/check-big.png0 http://w.sharethis.com/images/check-big.png3 ShareThishttp://w.sharethis.com/images/check-small.png
Dunedin cancer diagnostic company Pacific Edge remains focused on expansion into its key United States market, having recorded its first North American revenue stream.
For its full year to March, Pacific Edge's revenue was up 187% to $523,000, with after-tax losses growing 44% from $6.9 million to $9.3 million, as expected; but with the company retaining $20.4 million cash in hand to fund expansion.
Earlier this week Pacific Edge signed its fourth diagnostic testing deal with a major US health provider, and with two more deals under negotiation, potentially covers half the American population via their health providers.
While Pacific Edge has now booked total losses of $43.88 million during the past decade, chief executive David Darling remains adamant gross annual revenues of $100 million are ''readily attainable'' by the end of its fifth full year of trading.
''We've got a growing list of customers and remain very close to budget,'' Mr Darling said when contacted yesterday.
Pacific Edge's mainstay product is its diagnostic non-invasive CX bladder test, which is much cheaper than conventional tests, and it is developing variations on this test and also doing research into colorectal cancer.
Pacific Edge shares traded down 6c to 91c following yesterday's announcement.
Craigs Investment Partners broker Peter McIntyre said the $9.3 million loss was anticipated and the company was ''maintaining a strategic plan, and running to it''
''If Pacific Edge take CX bladder [development] elsewhere to other forms of cancer detection, that could be very big for them,'' Mr McIntyre said.
Mr Darling said the roll-out of services in the US had been the dominant component of Pacific Edge's commercialisation programme, and would remain so this financial year in order to build scale.
''As part of this we will be rapidly growing our US sales team and ramping up our sales efforts in the USA,'' he said.
''Significant funds'' would be used during the year to increase customer numbers, particularly the ''high volume user groups'', which were practices of 40 or more urologists.
As an example of increasing scale, he said in New Zealand there were about 40 urologists, compared with several practices across the US with 40-50 urologists per practice.
For the year to March, foreign exchange gains of $571,000 were booked, compared with a $33,000 loss a year earlier; with this year's foreign exchange gain larger than the $523,000 revenue.
When asked, Mr Darling said for a New Zealand company looking to repatriate funds the company had '' a very well defined, and sophisticated'' hedging strategy in place.
He declined to give an update on actual test numbers, since they began in the US in the second half of 2013, or to provide any guidance on expectations for the current year.
He said pricing per test ''varied hugely'' given different subsidies available and to divide revenue by the number of tests did not give an accurate picture.
Moosie, no point watching - this is one great trading stock so get into the rhythm.
Meanwhile, have a look at Serko's prospectus - Chairman buying $1m worth of shares at same level as investors in the IPO, and directors' shares and senior executives' are locked up until 2016.
Compare and contrast that with Snakk.
I think one of those is having second thoughts Mac--He sounded pretty disappointed with the results (and he probably knows the company better than any one.) Ive always respected his input and respect even more his being ''straight up'' with his viewpoint.
No one can accuse him of being in one camp or the other.
One thing that I cant shake off is that day when the big co. came on board and the SP started at 1.10 and crashed down to .99--Im not saying its insider trading ,but it sure seems like some one knew something.
Those flamingoes I sent you , Moosie , are not to be considered as red cards:)
Going from 1m over 4m to 14m puts it on an exponential trajectory and that would support high valuations. On that note, there was an interesting development in regards to certndx:
http://www.cafepharma.com/boards/sho....php?p=5073274
But like you said, it would be nice to hear why CMS coverage has not come through yet and get more details about the user programme.
Cms coverage was not expected to be completed before aug 2014. However, you never know it could be here today.
Swann welcomed Obama-care, but the legislative changes mean Pacific Edge has to wait longer and make changes to gain CMS accreditation, though he is hopeful it will be through early next year.
http://www.nzherald.co.nz/business/n...ectid=11178639
The thing I will be looking for in the full Annual Report is the number of tests conducted on trials (i.e wont be reported as revenue as they dont collect a fee). This is far more important than actual sales at this point imo.
Id be much happier seeing 200 sales and 5000 user tests than 2000 sales and 0 user tests for example. This would also indicate the demand that CS is talking about.
If the user tests is poor I would need to re-evalute my position.
EDIT: a lot of tin foil hats in here.
Snapiti can you expand on what smoke and mirrors is?
Appreciate your views
cheers
@ the feeling towards Snapiti generally.
Confirmation bias - is the tendency of people to favour information that confirms their beliefs or hypotheses.
I found your points and repetition incredibly frustrating until PEB broke the rules I was playing by and I pulled out (wait till it settles and at least starts trending upwards, I will miss the initial gains, but hey, I can sleep at night).
I will happily say I was probably looking for information that confirmed my own beliefs and found yours very irritating - as it did not match mine.
But now I'm out, I find your opinions much easier to swallow, funny that (definition above). The same is probably happening to a lot of people here. :-S